Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond. (13th July 2018)

• Record Type: Journal Article
• Authors: Wong, Hui-li; Christie, Michael; Gately, Lucy; Tie, Jeanne; Lee, Belinda; Semira, Christine; Lok, Sheau Wen; Wong, Rachel; Gibbs, Peter
• Is Part Of: Future oncology. Volume 14:Number 26(2018)
• Page Start: 2725
• Page End: 2739
• Publication Date: 2018-07-13
• Subjects: biomarkers -- gastrointestinal/colorectal -- pathology; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon-2018-0319
• Languages: English
• ISSNs: 1479-6694

Abstract

While mismatch repair (MMR) deficiency has been studied extensively, the assessment of MMR status in colorectal and other cancers remains highly relevant, particularly in light of recent data demonstrating that MMR deficiency is a strong predictor for treatment benefit with immune checkpoint inhibitors across multiple tumor types. In colorectal cancer, there is a growing consensus in support of routine MMR testing for Lynch syndrome screening, to inform prognosis and adjuvant chemotherapy use in early stage disease, and to predict response to immunotherapy in advanced disease. Here, we provide a review of the Ventana MMR Immunohistochemistry Panel, which was recently approved by the US FDA for use in Lynch syndrome screening.